Attached files
file | filename |
---|---|
EX-99.1 - ENDONOVO THERAPEUTICS, INC. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 19, 2016
ENDONOVO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 333-176954 | 45-2552528 | ||
(State or other jurisdiction | (Commission | (IRS Employer | ||
of incorporation) | File Number) | Identification No.) |
6320 Canoga Avenue, 15th Floor
Woodland Hills, CA 91367
(Address of principal executive office)(Zip Code)
Registrant’s telephone number, including area code: (800) 489-4774
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.02 Termination of a Material Definitive Agreement.
On August 19, 2019, we received a notice to terminate the binding letter agreement executed on July 9, 2016 (the “Letter Agreement”) with Rio Grande Neurosciences, Inc. (“RGN”) previously reported on a Current Report on Form 8-K dated July 9, 2016 and filed July 11, 2016. RGN, acting through its CEO, advised us that it would not proceed with the transactions contemplated by the Letter Agreement unless there were substantial modifications to their terms, including, but not limited to, the payment by us of substantial monies to RGN prior to closing and the entry into a more definitive agreement; and allowing RGN to seek other possible transactions in contravention of the non-circumvention of provisions of the Letter Agreement. We do not believe that there will be any liability to us as a result of the termination of the Letter Agreement. RGN has confirmed that the $500,000 note issued to RGN as an initial payment to RGN have been cancelled as a result of their notice to terminate the Letter Agreement.
Item 9.01 Financial Statements and Exhibits.
(a) | Financial Statements -None |
(b) | Exhibits |
99.1 | Press Release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 19, 2016
ENDONOVO THERAPEUTICS, INC. | ||
By: | /s/ Alan Collier | |
Alan Collier Chief Executive Officer |